InflaRx (IFRX) Asset Utilization Ratio (2018 - 2026)
InflaRx (IFRX) posted Asset Utilization Ratio of 0.89 for Q1 2026, up 11.65% sequentially from 0.8 in Q4 2025, and up 36.28% YoY from 0.66 in Q1 2025.
InflaRx (IFRX) Asset Utilization Ratio (2018 - 2026) Analysis & Trends
InflaRx has reported Asset Utilization Ratio for 9 years, with the latest figure at 0.89 in Q1 2026.
- Quarterly Asset Utilization Ratio rose 36.28% year-over-year to 0.89 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.89 (up 36.28% YoY) and the FY2025 annual result came in at 0.75, up 39.47% from the prior year.
- Asset Utilization Ratio advanced to 0.89 in Q1 2026 per IFRX's latest filing, from 0.8 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 611.8 in Q2 2024 and troughed at 62.18 in Q3 2022.
- A 5-year average of 124.21 and a median of 0.71 in 2025 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2023 and 2024: Asset Utilization Ratio soared 392822.31% in 2023, then tumbled 99.9% in 2024.
- Over 5 years, Asset Utilization Ratio stood at 0.13 in 2022, then surged by 392822.31% to 529.52 in 2023, then plunged by 99.87% to 0.67 in 2024, then rose by 19.23% to 0.8 in 2025, then increased by 11.65% to 0.89 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.89, 0.8, and 0.71 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | -0.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.89 |
| Dec 31, 2025 | 0.80 |
| Sep 30, 2025 | 0.71 |
| Jun 30, 2025 | 0.65 |
| Mar 31, 2025 | 0.66 |
| Dec 31, 2024 | 0.67 |
| Sep 30, 2024 | 0.52 |
| Jun 30, 2024 | 611.80 |
| Mar 31, 2024 | 539.20 |
| Dec 31, 2023 | 529.52 |
| Sep 30, 2023 | 500.55 |
| Jun 30, 2023 | 44.85 |
| Mar 31, 2023 | 54.20 |
| Dec 31, 2022 | 0.13 |
| Sep 30, 2022 | -62.18 |
| Jun 30, 2022 | -57.95 |
| Mar 31, 2022 | -53.50 |
| Dec 31, 2021 | -49.28 |
| Sep 30, 2021 | -99.85 |
| Jun 30, 2021 | -92.49 |